NR4A1 and neoplasm: Given that the 21-gene RS is a promising tool that can guide a chemotherapy decision in early-stage breast cancer patients with hormone receptor-positive and HER2-negative tumor, a shared-decision making with patients, using the multigene assay result and discussions about known risks and benefits of chemotherapy should be warranted in the era of personalized medicine.